SCYNEXIS, Inc. Share Price
NASDAQ: SCYX | Micro CapSCYNEXIS, Inc. Stock Performance
Open $5.38 | Prev. Close $5.23 | Circuit Range N/A |
Day Range $5.38 - $5.46 | Year Range $0.57 - $5.50 | Volume 6,441 |
Average Traded $5.38 |
SCYNEXIS, Inc. Share Price Today
As of 10 August 2026, SCYNEXIS, Inc.'s share price is $5.30. The stock opened at $5.38, compared to its previous close of $5.23. During today's trading session, SCYNEXIS, Inc.'s share price traded between $5.38 and $5.46, with an average price of $5.42. Over the past 52 weeks, the stock has recorded a high of $5.50 and a low of $0.57. In terms of performance, SCYNEXIS, Inc.'s share price has risen by 611.41% over the last six months and is up 537.79% on a year-on-year basis.
SCYNEXIS, Inc. Share Price Chart
SCYNEXIS, Inc. Stock Fundamentals & Key Indicators
Market Cap $264.65M | PE Ratio (TTM) -31.18 | Dividend Yield N/A |
EPS (TTM) $-0.17 | Revenue (TTM) $20.60M | Return On Equity (TTM) -17.44% |
Profit Margin -41.79% | Debt to Equity 0.12 | Quarterly Earnings Growth YoY -205.95% |
SCYNEXIS, Inc. Quarterly Profit & Loss
All figures in USD
SCYNEXIS, Inc. Annual Profit & Loss
All figures in USD
About SCYNEXIS, Inc.
SCYNEXIS, Inc., a biotechnology company, develops medicines to overcome and prevent difficult-to-treat and drug-resistant infections in the United States. It offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis (VVC) and recurrent VVC. The company's lead product candidate is Ibrexafungerp, a drug for the treatment of invasive candidiasis and/or candidemia, refractory invasive fungal infections, invasive aspergillosis, VVC, and recurrent VVC. It also develops SCY-247 to treat systemic fungal diseases. The company has licensing and collaboration agreements with GlaxoSmithKline Intellectual Property (No. 3) Limited, Merck Sharp & Dohme Corp., Hansoh (Shanghai) Health Technology Co., Ltd., Jiangsu Hansoh Pharmaceutical Group Company Limited, CJSC (R-Pharm), and Cypralis Limited for the development, manufacture, and commercialization of ibrexafungerp. SCYNEXIS, Inc. was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. The company was incorporated in 1999 and is headquartered in Jersey City, New Jersey.
SCYNEXIS, Inc. Historical Returns
| Month | Open | Close | Change % |
|---|---|---|---|
Aug 2026 | $4.81 | $5.42 | +10.84% |
Jul 2026 | $4.13 | $4.89 | +20.62% |
Jun 2026 | $5.26 | $4.05 | +471.79% |
May 2026 | $0.94 | $0.71 | -24.01% |
Apr 2026 | $0.89 | $0.93 | +2.53% |
Mar 2026 | $0.74 | $0.91 | +22.15% |
Feb 2026 | $0.70 | $0.74 | +4.78% |
Jan 2026 | $0.63 | $0.71 | +13.94% |
Dec 2025 | $0.67 | $0.62 | -11.74% |
Nov 2025 | $0.64 | $0.71 | +7.12% |
Oct 2025 | $0.80 | $0.66 | -15.28% |
Sep 2025 | $0.81 | $0.78 | -6.26% |